丙型肝炎病毒逃逸研究揭示人源单克隆抗体AR4A的分离株特异性耐药及高耐药屏障
研究在Huh7.5细胞中培养HCV核心-NS2重组体H77(1a型)/JFH1及高抗体易感的高变区1缺失变异体H77/JFH1∆HVR1和J6(2a型)/JFH1∆HVR1,观察交叉基因型反应性中和抗体AR4A的逃逸。长期AR4A暴露下H77/JFH1与H77/JFH1∆HVR1未产生耐药,而J6/JFH1∆HVR1出现包膜E2替换I696T或I696N,降低AR4A结合(I696N强于I696T)。结论认为I696位于AR4A表位内,该表位具有高耐药屏障,支持将其纳入理性HCV疫苗设计。
要点
- 长期AR4A暴露下H77/JFH1与H77/JFH1∆HVR1未产生耐药。
- J6/JFH1∆HVR1出现E2替换I696T或I696N,降低AR4A结合。
- I696N在J6/JFH1∆HVR1中赋予的AR4A耐药性强于I696T,而在J6/JFH1中相反。
核心结论
- I696位于AR4A表位内,该表位具有高耐药屏障,强化了将其纳入理性HCV疫苗设计的依据。
研究设计与样本
- 在Huh7.5细胞中培养HCV核心-NS2重组体H77(基因1a型)/JFH1及高抗体易感的高变区1缺失变异体H77/JFH1∆HVR1和J6(基因2a型)/JFH1∆HVR1,并进行AR4A逃逸研究。
主要发现
- 长期AR4A暴露的H77/JFH1与H77/JFH1∆HVR1未产生耐药。
- J6/JFH1∆HVR1出现包膜E2替换I696T或I696N,降低AR4A结合,I696N的降低程度大于I696T。
- I696N在J6/JFH1∆HVR1中赋予的AR4A耐药性强于I696T,而在J6/JFH1中I696T强于I696N。
- I696N而非I696T赋予J6/JFH1广泛增高的抗体中和易感性。
- I696N和I696T消除H77/JFH1的感染性,并广泛增高S52(基因3a型)/JFH1的中和易感性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Global control of hepatitis C virus (HCV) depends on development of a prophylactic vaccine. We studied escape for cross-genotype-reactive neutralizing antibody AR4A, providing valuable information for HCV vaccine design. We cultured HCV core-NS2 recombinants H77 (genotype 1a)/JFH1 or the highly antibody-susceptible hypervariable region 1 (HVR1)-deleted variants H77/JFH1∆HVR1 and J6(genotype 2a)/JFH1∆HVR1 in Huh7.5 cells with AR4A. Long-term AR4A exposure of H77/JFH1 and H77/JFH1∆HVR1 did not yield resistance. However, J6/JFH1∆HVR1 developed the envelope-E2 substitutions I696T or I696N, which reduced AR4A binding (I696N > I696T). I696N conferred greater AR4A resistance than I696T in J6/JFH1∆HVR1, whereas the reverse was observed in J6/JFH1. This was because I696N but not I696T conferred broadly increased antibody neutralization susceptibility to J6/JFH1. I696N and I696T abrogated infectivity of H77/JFH1 and broadly increased neutralization susceptibility of S52 (genotype 3a)/JFH1. In conclusion, I696 is in the AR4A epitope, which has a high barrier to resistance, thus strengthening the rationale for its inclusion in rational HCV vaccine designs.
引用
- Velázquez-Moctezuma R, Galli A, Law M, et al. Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance. J Infect Dis. 2019. PMID: 30102355. doi:10.1093/infdis/jiy481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。